Whitehawk Therapeutics Inc WHWK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
-
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
-
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
-
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
-
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
-
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Trading Information
- Previous Close Price
- $3.76
- Day Range
- $3.66–3.81
- 52-Week Range
- $1.87–5.50
- Bid/Ask
- $3.67 / $4.05
- Shares Outstanding
- 57.01M
- Market Cap
- $210.93M
- Volume/Avg
- 431,786 / 396,472
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.whitehawktx.com
Valuation
|
Metric
|
WHWK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
WHWK
Financial Strength
|
Metric
|
WHWK
|
|---|---|
Quick Ratio | 11.13 |
Current Ratio | 11.36 |
Interest Coverage | — |
Quick Ratio
WHWK
Profitability
|
Metric
|
WHWK
|
|---|---|
Return on Assets (Normalized) | −43.20% |
Return on Equity (Normalized) | −46.32% |
Return on Invested Capital (Normalized) | −50.41% |
Return on Assets
WHWK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G#&>C## | LOCK|>W&% | $128B | |||
| Moderna Inc
MRNA
| LOCK|^CQrSY | LOCK|kp | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#%r@S#c | LOCK|>Q$j | $76B | |||
| argenx SE ADR
ARGX
| LOCK|gR?S$HN | LOCK|@R# | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ySp!$X | LOCK|>Z | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Z^fVSF | LOCK|Rlk& | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&DGjJ#D | LOCK|Y$gp | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y%qs!q | LOCK|ST | $24B | |||
| Incyte Corp
INCY
| LOCK|j?Z%XF | LOCK|cj | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|q%&>CB | LOCK|^v | $15B |
United States